This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CERC-611

Cerecor Inc.

Drug Names(s): CERC611, CERC 611, LY3130418, LY 3130418, LY-3130418

Description: CERC-611 is a potent and selective Transmembrane AMPA Receptor Regulatory Proteins (“TARP”)-gamma 8-dependent AMPA receptor antagonist.

Deal Structure: Cerecor and Eli Lilly
In September 2016, Cerecor announced that it has acquired exclusive, worldwide rights from Eli Lilly to develop and commercialize LY3130418 (now designated as CERC-611). Under the terms of the agreement, Cerecor will immediately assume full development and commercialization responsibilities of CERC-611. Lilly will receive an upfront licensing fee as well as milestone and tiered royalty payments.

Partners: Eli Lilly & Company


CERC-611 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug